#United States #New York #The Gross Law Firm #Skye Bioscience #nimacimab

Investors Urged to Join Class Action Against Skye Bioscience Inc.

In an important alert for investors, The Gross Law Firm has announced significant legal action pertaining to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE). If you acquired shares during the specified class period from November 4, 2024, to October 3, 2025, you are strongly encouraged to contact the firm regarding your rights and the potential for recovery in a pending class action lawsuit.

Overview of Allegations

The allegations made in the upcoming class action are quite serious. It is claimed that Skye Bioscience, under the leadership of its executives, has misled investors regarding the efficacy of its lead product candidate, nimacimab. According to the complaint, the company’s public statements were allegedly misleading and did not accurately represent the drug’s clinical, regulatory, and commercial prospects. The following key points outline the core issues:

1. Efficacy Misrepresentation: Shareholders assert that nimacimab's effectiveness was overstated, suggesting that investors were not provided with a clear picture of its capabilities, which were presented as better than they actually are.
2. Lack of Disclosure: The complaint notes a failure to disclose critical information regarding the drug's performance, which has implications not only for investor trust but for the company's financial health.
3. Subsequent Consequences: The fallout from these misleading statements may have led to an artificial inflation of Skye's stock value, adversely impacting the financial standing of investors when true performance metrics became known.

Registration and Next Steps for Shareholders

If you are among these investors, it is crucial to register for the class action before the impending deadline of January 16, 2026. Registration will not only enhance your ability to potentially recover losses but also ensures that you are kept informed on the progress of the case through portfolio monitoring software. This monitoring service will provide status updates throughout the duration of the case lifecycle, keeping you engaged and informed.

It’s important to note that participation in the case does not require you to become a lead plaintiff. This option is available, but it is not a necessity for you to gain recovery if your claims are successful.

The Gross Law Firm's Advocacy

The Gross Law Firm is recognized on a national level for advocating on behalf of investors who have been affected by deceitful business practices. Their mission focuses on protecting the rights of individuals who have incurred losses due to misleading financial communications. The firm maintains a commitment to holding corporations accountable for their behavior, advocating for good corporate governance, and ensuring that those affected receive justice.

As the legal landscape for corporate accountability evolves, The Gross Law Firm represents a critical resource for stakeholders who sense that their interests have been compromised.

Why Act Now?

Delaying could potentially lead to a missed opportunity for recovery. However, navigating stockholder lawsuits can be complex and daunting, especially in cases involving substantial corporate misrepresentation. With a library of resources and a dedicated team of legal professionals, The Gross Law Firm is dedicated to ensuring your voice is heard in the financial sector.

If you feel you are eligible, do not hesitate; consider reaching out to The Gross Law Firm immediately. Here’s how you can get in touch:

• - Website: Contact The Gross Law Firm
• - Email: Email for Inquiries
• - Phone: (646) 453-8903

The firm is ready to assist you in claiming your rightful place in this prospective legal action. Protect your investments and make your voice count today.